Halia Therapeutics has unveiled a $30 million Series C funding round to further develop their innovative range of treatments for inflammation.

Meclizine is a small molecule drug that acts as an antagonist of histamine (H1) receptors.

Bio-Thera Solutions has launched an early-stage clinical study, specifically Phase 1B/2A, for its novel monoclonal antibody, BAT6026, aimed at OX40 for treating individuals experiencing moderate to intense eczema.

Rosuvastatin, sold as Ezallor and Crestor, is a small molecule inhibiting liver cholesterol synthesis by blocking HMG-CoA reductase enzyme.

Recent findings on Genentech's drug Vabysmo indicate persistent efficacy in reducing retinal swelling and enhancing eyesight for those with Retinal Vein Occlusion.

Escitalopram, marketed under the trade name Esertia, is an orally administered selective serotonin reuptake inhibitor.

RS Oncology Confirms Initial Participant Receives Dosage in Stage 2 Trial (MITOPE) Examining RSO-021 in Malignant Chest Tumor and Lung Metastases Therapy.

Ketamine is a small molecule drug that acts as a modulator at the N-methyl-D-aspartate (NMDA) receptor.

Sirius Therapeutics has initiated a first-stage clinical study for an advanced, extended-duration Factor XI siRNA anticoagulant, aimed at addressing thromboembolic conditions.

Mirtazapine acts as an alpha-2 adrenergic receptor (ADRA2) antagonist, causing the release of norepinephrine and serotonin in the brain.

Takeda Pharmaceuticals and Protagonist Therapeutics have signed a global licensing and partnership deal for the advanced experimental blood disorder medication, Rusfertide.

Alprazolam is an agonist at the GABAA receptor, a key player in the inhibitory neurotransmitter gamma-aminobutyric acid (GABA) pathway.